[go: up one dir, main page]

NO20045082L - Preparat basert pa substituerte 1,3-difenylprop-2-en-1-on-derivater, samt fremgangsmate for fremstilling og anvendelse derav - Google Patents

Preparat basert pa substituerte 1,3-difenylprop-2-en-1-on-derivater, samt fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO20045082L
NO20045082L NO20045082A NO20045082A NO20045082L NO 20045082 L NO20045082 L NO 20045082L NO 20045082 A NO20045082 A NO 20045082A NO 20045082 A NO20045082 A NO 20045082A NO 20045082 L NO20045082 L NO 20045082L
Authority
NO
Norway
Prior art keywords
preparation
diphenylprop
derivatives
substituted
methods
Prior art date
Application number
NO20045082A
Other languages
English (en)
Other versions
NO334650B1 (no
Inventor
Jamila Najib
Karine Caumont-Bertrand
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of NO20045082L publication Critical patent/NO20045082L/no
Publication of NO334650B1 publication Critical patent/NO334650B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen vedrører preparater som inneholder substituerte 1,3-difenylprop-2-en-1-on-derivater for terapeutisk anvendelse. Preparatene ifølge oppfinnelsen er særlig anvendelige til å forebygge eller behandle kardiovaskulære sykdommer, syndrom X, restenose, diabetes, fettsyke, hypertensjon, betennelsessykdommer, kreft eller neoplasma (godartede eller ondartede tumorer), neurodegenerative, dermatologiske sykdommer og forstyrrelser relatert til oksidativt stress og f.eks. hudaldring, særlig på kosmetikkområdet (opptreden av rynker og lignende).
NO20045082A 2002-07-08 2004-11-22 Preparat for behandling eller profylakse av en patologi relatert til betennelse, neurodegenerasjon, dereguleringer av lipid og/eller glukosemetabolisme, celleproliferasjon og/eller differensiering og/eller hud- eller sentral-nervesystemaldring, omfattende, i en farmasøytisk akseptabel bærer, minst ett substituert 1,3-difenylprop-2-en-1-on-derivat NO334650B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0208570A FR2841784B1 (fr) 2002-07-08 2002-07-08 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
PCT/FR2003/002128 WO2004005243A2 (fr) 2002-07-08 2003-07-08 Composition a base de derives de 1,3-diphenylprop-2-en-one substitues

Publications (2)

Publication Number Publication Date
NO20045082L true NO20045082L (no) 2004-12-27
NO334650B1 NO334650B1 (no) 2014-05-05

Family

ID=29725282

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045082A NO334650B1 (no) 2002-07-08 2004-11-22 Preparat for behandling eller profylakse av en patologi relatert til betennelse, neurodegenerasjon, dereguleringer av lipid og/eller glukosemetabolisme, celleproliferasjon og/eller differensiering og/eller hud- eller sentral-nervesystemaldring, omfattende, i en farmasøytisk akseptabel bærer, minst ett substituert 1,3-difenylprop-2-en-1-on-derivat

Country Status (24)

Country Link
US (3) US7632870B2 (no)
EP (1) EP1519908B1 (no)
JP (1) JP4907083B2 (no)
KR (1) KR100947907B1 (no)
CN (1) CN1688532B (no)
AT (1) ATE364588T1 (no)
AU (1) AU2003264699B2 (no)
BR (1) BRPI0312399B8 (no)
CA (1) CA2490993C (no)
CY (1) CY1108051T1 (no)
DE (1) DE60314420T2 (no)
DK (1) DK1519908T3 (no)
EA (1) EA012699B1 (no)
ES (1) ES2287529T3 (no)
FR (1) FR2841784B1 (no)
IL (1) IL165454A (no)
MX (1) MXPA05000425A (no)
NO (1) NO334650B1 (no)
NZ (1) NZ538052A (no)
PL (1) PL207707B1 (no)
PT (1) PT1519908E (no)
SI (1) SI1519908T1 (no)
WO (1) WO2004005243A2 (no)
ZA (1) ZA200501081B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
WO2005073184A1 (fr) * 2004-01-08 2005-08-11 Genfit Composes derives de 1,3-diphenylprop-2-en-1-one, preparation et utilisations
JP5380069B2 (ja) 2005-03-11 2014-01-08 ハワード フローリー インスティチュート フラボノイド化合物およびその使用
AU2010323066B2 (en) 2009-11-26 2014-12-11 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2011080276A1 (en) 2009-12-29 2011-07-07 Genfit Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
WO2012007365A1 (en) * 2010-07-12 2012-01-19 F. Hoffmann-La Roche Ag 1-hydroxyimino-3-phenyl-propanes
JP6158801B2 (ja) 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
MX2014004853A (es) * 2011-10-26 2014-05-27 Hoffmann La Roche 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
BR112015010947A2 (pt) 2012-11-13 2018-06-05 Nusirt Sciences Inc composições e métodos para aumentar o metabolismo energético.
EP2948137B1 (en) * 2013-01-18 2018-11-14 Genfit Methods of treatment of fibrosis and cancers
RU2015143836A (ru) 2013-03-15 2017-04-27 Нусерт Сайенсиз, Инк. Лейцин и никотиновая кислота для снижения уровня липидов
WO2015131152A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
WO2017143038A1 (en) 2016-02-16 2017-08-24 Concert Pharmaceuticals, Inc. Deuterated gft-505
EP3985126A1 (en) 2016-03-30 2022-04-20 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
ES2989468T3 (es) * 2016-04-16 2024-11-26 Univ Florida Métodos para mejorar la potencia biológica de virus adenoasociados recombinantes producidos en un sistema baculovírico
CN108658908B (zh) * 2017-07-31 2019-05-10 广州必贝特医药技术有限公司 1，3-二取代烯酮类化合物及其应用
CN109316601B (zh) * 2017-07-31 2021-11-09 武汉朗来科技发展有限公司 药物组合物及其用途
EP3719010B1 (en) 2017-11-30 2023-07-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Aromatic compound, pharmaceutical composition thereof and use thereof
US12030840B2 (en) 2018-08-03 2024-07-09 Genfit Elafibranor salts
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN115003653A (zh) 2020-02-10 2022-09-02 基恩菲特公司 艾拉菲诺的多晶型物
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558612A (en) * 1968-05-22 1971-01-26 Dow Chemical Co Substituted phenoxyacetic acids
CH593224A5 (no) * 1973-10-30 1977-11-30 Taisho Pharmaceutical Co Ltd
US3994955A (en) * 1975-01-20 1976-11-30 G. D. Searle & Co. Substituted phenoxydialkylacetic acids and esters
JPS5278856A (en) * 1975-12-26 1977-07-02 Taisho Pharmaceut Co Ltd Preparation of chalcone ethers
US4190671A (en) * 1977-03-17 1980-02-26 Biorex Laboratories Limited Chalcone derivatives
JPS5419947A (en) * 1977-07-16 1979-02-15 Taisho Pharmaceut Co Ltd Chalcone derivatives
US4163859A (en) * 1977-07-18 1979-08-07 G. D. Searle & Co. Phenoxyldialkyl acetic acids and esters
GB8426424D0 (en) * 1984-10-19 1984-11-28 Biorex Laboratories Ltd Chalcone derivatives
JPS6310720A (ja) * 1986-07-01 1988-01-18 Nippon Kayaku Co Ltd ５−リポキシゲナ−ゼ阻害剤および抗アレルギ−剤
JPH023670A (ja) 1988-06-22 1990-01-09 Nippon Oil & Fats Co Ltd アルキルチオカルコン誘導体
JPH0742227B2 (ja) * 1988-11-25 1995-05-10 日本ハイポックス 腎臓疾患治療剤
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
US5731454A (en) * 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
JPH0442229A (ja) * 1990-06-08 1992-02-12 Fujitsu Ltd レジスト材料およびパターンの形成方法
JPH05255655A (ja) * 1992-03-12 1993-10-05 Kanebo Ltd 紫外線吸収剤
JPH06122623A (ja) * 1992-10-09 1994-05-06 Minofuaagen Seiyaku Honpo:Goushi 抗腫瘍剤
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
DE4327365A1 (de) * 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
CN1327384A (zh) * 1998-10-20 2001-12-19 韩国科学技术研究院 作为血浆高密度脂蛋白浓度增高剂的生物类黄酮
EP1254658B1 (en) * 2000-01-27 2008-09-24 Takara Bio Inc. Remedies for the treatment of nerve diorders
IL153565A0 (en) * 2000-06-20 2003-07-06 Atherogenics Inc 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
EP1254759B1 (de) 2001-05-03 2009-03-18 Leister Process Technologies Düse zum Schweissen von Kunststoffbahnen oder -folien
FR2841900B1 (fr) * 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr) * 2003-07-08 2005-09-09 Genfit S A PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one

Also Published As

Publication number Publication date
DE60314420D1 (de) 2007-07-26
BRPI0312399B1 (pt) 2020-03-31
EA012699B1 (ru) 2009-12-30
JP4907083B2 (ja) 2012-03-28
BRPI0312399B8 (pt) 2021-05-25
EA200500170A1 (ru) 2005-10-27
EP1519908B1 (fr) 2007-06-13
US20100120909A1 (en) 2010-05-13
NO334650B1 (no) 2014-05-05
FR2841784A1 (fr) 2004-01-09
CY1108051T1 (el) 2013-09-04
PL207707B1 (pl) 2011-01-31
ZA200501081B (en) 2007-04-25
AU2003264699A1 (en) 2004-01-23
WO2004005243A3 (fr) 2004-04-22
IL165454A (en) 2012-12-31
US8106097B2 (en) 2012-01-31
ATE364588T1 (de) 2007-07-15
US20120129932A1 (en) 2012-05-24
AU2003264699B2 (en) 2009-09-24
FR2841784B1 (fr) 2007-03-02
JP2005532386A (ja) 2005-10-27
KR20050019818A (ko) 2005-03-03
CN1688532B (zh) 2012-07-11
US20050171149A1 (en) 2005-08-04
CA2490993A1 (fr) 2004-01-15
DK1519908T3 (da) 2007-10-15
US8461212B2 (en) 2013-06-11
DE60314420T2 (de) 2008-02-28
US7632870B2 (en) 2009-12-15
WO2004005243A2 (fr) 2004-01-15
NZ538052A (en) 2007-09-28
BR0312399A (pt) 2005-04-12
ES2287529T3 (es) 2007-12-16
MXPA05000425A (es) 2005-07-22
KR100947907B1 (ko) 2010-03-17
PL373465A1 (pl) 2005-09-05
EP1519908A2 (fr) 2005-04-06
SI1519908T1 (sl) 2007-08-31
CN1688532A (zh) 2005-10-26
PT1519908E (pt) 2007-09-04
CA2490993C (fr) 2012-09-18
IL165454A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
NO20045082L (no) Preparat basert pa substituerte 1,3-difenylprop-2-en-1-on-derivater, samt fremgangsmate for fremstilling og anvendelse derav
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
NO20074446L (no) DR5-antistoffer og anvendelser derav
AU2002258066A1 (en) Dermatological and cosmetic compositions
WO2005033102A3 (en) Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
NO20082082L (no) Modulatorer for ATP-bindingskassettstransportere
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
EP1470146B8 (en) Antibodies against the muc18 antigen
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
NO20073574L (no) Triazolsubstituerte aminobenzofenonforbindelser
ATE339418T1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
WO2003024395A8 (en) Linked biaryl compounds
WO2006012577A3 (en) Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2004060890A8 (en) 2-oxopyridin-3-yl thia (di) azole derivates for use in the treatment of cell proliferation and apoptosis related diseases
WO2005009460A3 (en) Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
WO2004067564A3 (en) Compositions against cancer antigen liv-1 and uses thereof
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2004073593A3 (fr) Aminopropanediols acyles et de leurs analogues azotes et sulfures pour diverses applications therapeutiques
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
NO20055650L (no) Ruteinum (II)-komplekser for behandling av tumorer
GB2430365B (en) High-purity texaphyrin metal complexes
ATE531766T1 (de) Hochreine texaphyrinmetallkomplexe

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees